Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Kodiak Sciences Inc. operates as a clinical stage biopharmaceutical company. The Company specializes in novel therapeutics to treat chronic and high-prevalence retinal diseases. Kodiak Sciences serves customers in the United States.
Website: kodiak.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 31.0% (LTM)

Entry Point: Share price is 2 326.4% higher than minimum and 13.7% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders sold company shares on $2.2 mln (-0.115% of cap.)

Key Financials (Download financials)

Ticker: KOD
Share price, USD:  (+8.2%)33.97
year average price 19.72  


year start price 3.68 2025-06-12

min close price 3.53 2025-06-18

max close price 39.34 2026-05-13

current price 33.19 2026-06-12
Common stocks: 51 953 604

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 1 724
Net Debt ($m): -803
EV (Enterprise Value): 921
Price to Book: 68.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-06zacks.com

KOD Stock Up 24% in 3 Months: Here's What You Need to Know

2026-01-12seekingalpha.com

Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-18prnewswire.com

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

2025-12-16prnewswire.com

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

2025-11-12prnewswire.com

Kodiak Sciences to Present at Upcoming Investor Conferences

2025-10-31youtube.com

The Big 3: GOOGL, KOD, FTK

2025-08-19prnewswire.com

Kodiak Sciences to Present at American Chemical Society Fall 2025

2025-08-14zacks.com

Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

2025-06-25prnewswire.com

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

2025-06-13zacks.com

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-13 2024-11-14 2024-08-14 2024-05-15 2023-11-14 2023-08-14 2023-05-15 2022-11-09 2022-08-09
acceptedDate 2025-11-13 16:12:38 2025-08-13 16:11:10 2025-03-27 16:20:20 2024-11-14 16:10:21 2024-08-14 16:10:20 2024-05-15 16:15:40 2023-12-29 19:00:00 2023-11-14 16:30:32 2023-08-14 16:33:01 2023-05-15 16:11:03 2023-03-28 16:31:31 2022-11-09 16:15:15 2022-08-09 17:02:28 2022-03-01 16:31:19 2021-03-01 17:23:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 7M 7M 27M 0 7M 7M 26M 7M 7M 0 11M 0 0 9M 4M
grossProfit -7M -7M -27M 0 -7M -7M -26M -7M -7M 0 -11M 0 0 -9M -4M
grossProfitRatio 0 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 50M 43M 126M 32M 33M 30M 206M 36M 67M 57M 268M 62M 74M 217M 107M
generalAndAdministrativeExpenses 0 0 0 15M 15M 16M 71M 18M 18M 18M 0 18M 18M 0 0
sellingAndMarketingExpenses 0 0 0 0 0 -7M 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 6M 34M 15M 15M 9M 71M 18M 18M 18M 63M 18M 18M 41M 24M
otherExpenses 0 0 0 0 0 -337 000 -26M -38 000 -35 000 222 000 0 0 0 0 0
operatingExpenses 56M 49M 160M 47M 48M 39M 251M 55M 85M 75M 330M 79M 92M 258M 132M
costAndExpenses 62M 56M 187M 47M 48M 46M 277M 55M 85M 75M 341M 79M 92M 267M 136M
interestIncome 917 000 1M 11M 3M 3M 3M 17M 5M 5M 4M 7M 2M 1M 298 000 3M
interestExpense 0 0 0 0 0 0 13 000 -5000 4000 4000 18 000 4000 5000 22 000 25 000
depreciationAndAmortization 7M 7M 27M 7M 7M 7M 26M 7M 7M 4M 11M 5M 3M 9M 4M
ebitda -55M -48M -150M -37M -38M -39M -235M -55M -80M -71M -323M -74M -88M -258M -129M
ebitdaratio 0 0 0 0 0 0 0 0 0 0
operatingIncome -62M -56M -187M -47M -48M -46M -277M -55M -85M -75M -341M -79M -92M -267M -136M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 895 000 1M 11M 3M 3M 3M 17M 4M -35 000 4M 8M 2M 1M 61 000 3M
incomeBeforeTax -61M -54M -176M -44M -45M -43M -260M -50M -80M -71M -334M -77M -91M -267M -133M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 7M 0 -7M -7M -4M 0 -79M 0 0 0
netIncome -61M -54M -176M -44M -45M -43M -260M -50M -80M -67M -334M 2M -91M -267M -133M
netIncomeRatio 0 0 0 0 0 0 0 0 0 0
eps -1.16 -1.03 -3.35 -0.84 -0.86 -0.82 -4.97 -0.95 -1.53 -1.28 -6.39 -1.47 -1.74 -5.16 -2.91
epsdiluted -1.16 -1.03 -0.84 -0.86 -0.82 -0.95 -1.53 -1.28 0.035 -1.74
weightedAverageShsOut 53M 53M 53M 53M 53M 53M 52M 52M 52M 52M 52M 52M 52M 52M 46M
weightedAverageShsOutDil 53M 53M 53M 53M 53M 53M 52M 52M 52M 52M 52M 52M 52M 52M 46M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2023-12-31 2023-03-28 2022-03-01 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 11M 17M 7M 276 000 3M
ebit -176M -260M -334M -267M -133M
nonOperatingIncomeExcludingInterest -11M -17M -8M -83 000 -3M
netIncomeFromContinuingOperations -176M -260M -334M -267M -133M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -176M -260M -334M -267M -133M
epsDiluted -3.35 -4.97 -6.39 -5.16 -2.91

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-13 2024-11-14 2024-08-14 2024-05-15 2023-11-14 2023-08-14 2023-05-15 2022-11-09 2022-08-09
acceptedDate 2025-11-13 16:12:38 2025-08-13 16:11:10 2025-03-27 16:20:20 2024-11-14 16:10:21 2024-08-14 16:10:20 2024-05-15 16:15:40 2023-12-29 19:00:00 2023-11-14 16:30:32 2023-08-14 16:33:01 2023-05-15 16:11:03 2023-03-28 16:31:31 2022-11-09 16:15:15 2022-08-09 17:02:28 2022-03-01 16:31:19 2021-03-01 17:23:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 72M 104M 168M 198M 219M 246M 286M 346M 379M 317M 190M 178M 173M 732M 944M
shortTermInvestments 0 0 0 0 0 0 0 0 0 105M 289M 359M 425M 0 25M
cashAndShortTermInvestments 72M 104M 168M 198M 219M 246M 286M 346M 379M 421M 479M 537M 598M 732M 969M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 4M 4M 4M 5M 5M 6M 4M 5M 8M 10M 7M 7M 6M 3M 0
totalCurrentAssets 76M 108M 172M 202M 225M 252M 289M 351M 387M 431M 486M 545M 604M 735M 972M
propertyPlantEquipmentNet 127M 134M 149M 155M 162M 168M 175M 182M 187M 194M 116M 117M 118M 108M 79M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 6M 6M 0 0 6M 6M 6M 6M 0 6M 0 0 6M 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 15M 9M 9M 15M 15M 9M 9M 9M 9M 16M 59M 62M 60M 55M 17M
totalNonCurrentAssets 142M 149M 164M 170M 177M 183M 190M 197M 203M 209M 181M 179M 178M 169M 95M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 218M 257M 336M 373M 402M 435M 479M 548M 590M 640M 667M 724M 782M 904M 1 067M
accountPayables 10M 5M 4M 3M 2M 2M 14M 39M 12M 6M 9M 16M 21M 12M 9M
shortTermDebt 12M 11M 0 0 20M 10M 10M 9M 8M 8M 10M 9M 6M 4M 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 20M 15M 0 21M -447 000 13M 12M 23M 54M 55M 27M 41M 43M 42M 0
totalCurrentLiabilities 42M 31M 26M 24M 21M 25M 42M 71M 74M 69M 52M 66M 70M 65M 31M
longTermDebt 50M 54M 0 63M 66M 100M 100M 74M 77M 79M 100M 79M 81M 100M 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 102M 102M 100M 100M 100M 69M 0 100M 100M 100M 162 000 154M 100M 210 999 100M
totalNonCurrentLiabilities 152M 155M 160M 163M 166M 169M 172M 174M 177M 179M 178M 179M 181M 176M 175M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 62M 65M 70M 63M 76M 69M 72M 83M 85M 87M 78M 88M 87M 76M 77M
totalLiabilities 194M 186M 185M 187M 187M 194M 214M 245M 251M 248M 230M 244M 251M 241M 207M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000
retainedEarnings -1 502M -1 441M -1 329M -1 285M -1 241M -1 196M -1 153M -1 093M -1 043M -963M -892M -822M -745M -558M -291M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 0 -96 000 -1M -3M -2M 0 53 000
othertotalStockholdersEquity 1 526M 1 511M 1 470M 1 455M 1 437M 1 395M -5000 1 355M 1 304M 1 277M
totalStockholdersEquity 24M 70M 150M 185M 215M 241M 266M 302M -1 043M 393M 436M 480M 531M 663M 861M
totalEquity 24M 70M 150M 185M 215M 241M 266M 302M -1 043M 393M 436M 480M 531M 663M 861M
totalLiabilitiesAndStockholdersEquity 218M 257M 373M 402M 435M 548M -792M 640M 724M 782M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 218M 257M 336M 373M 402M 435M 479M 548M -792M 640M 667M 724M 782M 904M 1 067M
totalInvestments 0 6M 6M 0 6M 6M 6M 6M 6M 105M 295M 359M 0 6M 25M
totalDebt 62M 65M 70M 73M 76M 178M 182M 83M 85M 87M 188M 88M 87M 180M 77M
netDebt -10M -39M -98M -124M -143M -68M -104M -262M -294M -230M -3M -91M -86M -552M -867M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2023-12-31 2023-03-28 2022-03-01 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 3M
totalPayables 4M 14M 9M 12M 9M
otherPayables 0 0 0 0 0
accruedExpenses 11M 6M 6M 6M 20M
capitalLeaseObligationsCurrent 11M 0 0 0 2M
capitalLeaseObligationsNonCurrent 60M 72M 78M 76M 75M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 479M 1 418M 1 330M 1 222M 1 152M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD KOD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-13 2024-11-14 2024-08-14 2024-05-15 2023-11-14 2023-08-14 2023-05-15 2022-11-09 2022-08-09
acceptedDate 2025-11-13 16:12:38 2025-08-13 16:11:10 2025-03-27 16:20:20 2024-11-14 16:10:21 2024-08-14 16:10:20 2024-05-15 16:15:40 2023-12-29 19:00:00 2023-11-14 16:30:32 2023-08-14 16:33:01 2023-05-15 16:11:03 2023-03-28 16:31:31 2022-11-09 16:15:15 2022-08-09 17:02:28 2022-03-01 16:31:19 2021-03-01 17:23:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -61M -54M -176M -44M -45M -43M -260M -50M -80M -71M -334M -77M -91M -267M -133M
depreciationAndAmortization 7M 7M 27M 7M 7M 7M 26M 7M 7M 6M 11M 3M 3M 9M 4M
deferredIncomeTax 0 0 0 0 0 0 0 -314 000 -328 000 0 0 0 0 0 -51 000
stockBasedCompensation 0 16M 60M 15M 18M 18M 89M 14M 26M 26M 106M 26M 26M 61M 31M
changeInWorkingCapital 8M -3M -28M 28M -7M -22M -7M -4M 6M -8M 12M -5M 7M 14M 15M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 5M -1M -10M 2M -791 000 -11M 6M -435 000 5M -2M 2M -6M 6M -2M 5M
otherWorkingCapital 3M -1M -19M 27M -6M -11M -13M -3M 964 000 2M 10M 1M 0 17M 10M
otherNonCashItems 14M 0 355 000 -27M 211 000 43M -840 000 314 000 -314 000 -514 000 -2M -421 000 -301 000 198 000 49 000
netCashProvidedByOperatingActivities -33M -35M -117M -21M -26M -40M -154M -33M -42M -47M -206M -53M -55M -182M -83M
investmentsInPropertyPlantAndEquipment -60 000 -133 000 -400 000 -180 000 -49 000 -22 000 -41M -226 000 -1M -12M -47M -7M -16M -63M -7M
acquisitionsNet 0 0 0 0 0 0 -290 653 0 0 77 000 0 0 0 0 3M
purchasesOfInvestments 0 0 -355 000 0 0 0 -49M 0 0 -49M -428M 0 -428M 0 -86M
salesMaturitiesOfInvestments 0 0 0 0 0 0 340M 0 105M 235M 138M 66M 0 25M 198M
otherInvestingActivites 0 0 -25 000 -211 000 -144 000 0 0 -77 000 0 0
netCashUsedForInvestingActivites -60 000 -133 000 -205 000 -260 000 -166 000 -226 000 104M 173M 59M -444M
debtRepayment 0 0 0 0 0 -3M -2M 0 0 0
commonStockIssued 813 000 120 000 -97 000 59 000 38 000 0 182 000 0 0 0
commonStockRepurchased 0 0 0 59 000 0 0 0 0 0 0 0 0 0 0 -487 000
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 -59 000 59 000 38 000 2M 2M -3000 78 000 54 000
netCashUsedProvidedByFinancingActivities 813 000 120 000 0 59 000 38 000 -12 000 170 000 -3000 78 000 54 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 -36M 0 0 0 0 0 0
netChangeInCash -32M -35M -118M -15M -27M -40M 95M -33M 62M 126M -541M 6M -499M -213M 739M
cashAtEndOfPeriod 72M 110M 174M 204M 219M 246M 286M 352M 385M 323M 190M 185M 179M 738M 951M
cashAtBeginningOfPeriod 104M 145M 292M 219M 246M 286M 190M 385M 323M 197M 732M 179M 678M 951M 212M
operatingCashFlow -33M -35M -117M -21M -26M -40M -154M -33M -42M -47M -206M -53M -55M -182M -83M
capitalExpenditure -59 999 -133 000 -400 000 -180 000 -49 000 -22 000 -41M -226 000 -1M -12M -47M -7M -16M -63M -7M
freeCashFlow -33M -35M -118M -21M -27M -40M -196M -33M -43M -59M -254M -60M -71M -246M -90M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2023-12-31 2023-03-28 2022-03-01 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 290 653 616 000 0 -3M
netCashProvidedByInvestingActivities -755 000 249M -337M -39M 105M
netDebtIssuance 0 0 0 0 -5000
longTermNetDebtIssuance 0 0 0 0 -5000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 501 000 242 000 2M 0 612M
netCommonStockIssuance 501 000 242 000 2M 0 612M
commonStockIssuance 501 000 242 000 2M 0 612M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 -211 000 -49 000 8M 106M
netCashProvidedByFinancingActivities 501 000 31 000 2M 8M 717M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 22 000 0

Earning call transcript

2023 q4
2024-03-28 ET (fiscal 2023 q4)

Press-releases

Show financial reports only

2026-03-26 ET
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
2026-02-04 ET
Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
2026-01-07 ET
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-12-18 ET
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
2025-12-16 ET
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
2025-12-15 ET
Kodiak Sciences Announces Proposed Public Offering of Common Stock
2025-11-13 21:05 ET
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
2025-11-12 ET
Kodiak Sciences to Present at Upcoming Investor Conferences
2025-11-05 ET
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
2025-09-15 ET
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
2025-09-02 ET
Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)
2025-08-19 ET
Kodiak Sciences to Present at American Chemical Society Fall 2025
2025-08-13 ET
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results
2025-07-10 ET
Kodiak Sciences to Host Investor R&D Day on July 16, 2025
2025-06-25 ET
Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
2025-05-29 ET
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
2025-05-14 ET
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
2025-05-01 ET
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
2025-03-27 ET
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
2025-03-10 ET
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
2025-02-04 ET
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
2025-01-07 ET
Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
2024-12-09 ET
Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases
2024-11-14 21:01 ET
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
2024-11-11 11:15 ET
Kodiak Sciences to Participate in Upcoming Investor Conferences
2024-10-14 21:35 ET
Kodiak Sciences to Present at Innovate Retina 2024
2024-09-23 10:00 ET
Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
2024-09-17 20:05 ET
Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City
2024-08-14 20:01 ET
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results
2024-05-29 20:36 ET
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
2024-05-15 20:01 ET
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
2024-05-13 23:32 ET
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
2024-05-02 20:30 ET
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
2024-03-28 10:30 ET
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
2024-03-26 10:15 ET
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
2024-01-30 11:30 ET
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
2024-01-04 21:15 ET
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-21 21:15 ET
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-14 21:01 ET
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
2023-11-06 10:00 ET
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission
2023-11-02 03:21 ET
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING
2023-10-11 10:00 ET
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
2023-09-08 10:00 ET
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-09-07 10:00 ET
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion
2023-08-14 20:01 ET
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights
2023-07-24 10:00 ET
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program
2023-05-30 20:15 ET
Kodiak Sciences to Present at Upcoming Investor Conferences
2023-05-15 20:01 ET
Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights
2023-04-21 11:30 ET
Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting
2023-04-03 11:30 ET
Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases
2023-03-28 20:08 ET
Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
2023-02-09 12:30 ET
Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting
2023-01-04 12:00 ET
Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-11-16 21:30 ET
Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference
2022-11-09 21:01 ET
Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights
2022-09-07 20:05 ET
Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference
2022-08-18 21:47 ET
Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)
2022-08-09 20:33 ET
Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights
2022-08-08 10:30 ET
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion
2022-08-05 20:30 ET
Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy
2022-05-27 12:00 ET
Kodiak Sciences to Present at the Jefferies Global Healthcare Conference
2022-05-19 12:00 ET
Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases
2022-05-10 20:10 ET
Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights
2022-04-29 09:30 ET
Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences
2022-03-01 21:10 ET
Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
2022-02-23 11:00 ET
Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration
2022-02-03 10:30 ET
Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema
2022-01-03 21:05 ET
Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-16 10:30 ET
Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion
2021-11-09 21:30 ET
Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights
2021-11-08 21:05 ET
Kodiak Sciences to Present at Upcoming Conferences
2021-09-01 09:45 ET
Kodiak Sciences Announces New Long-Term Performance Incentive Plan
2021-08-31 09:02 ET
Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-09 20:01 ET
Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights
2021-05-20 23:00 ET
Kodiak Sciences to Present at Upcoming Conferences
2021-05-10 09:30 ET
Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights
2021-04-21 22:59 ET
Kodiak Sciences to Present at Upcoming Conferences
2021-03-02 21:12 ET
Kodiak Sciences to Present at Upcoming Conferences
2021-03-01 10:30 ET
Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
2021-02-02 12:14 ET
Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
2021-01-05 13:02 ET
Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference
2020-11-20 21:03 ET
Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2020-11-20 ET
Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2020-11-18 02:02 ET
Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock
2020-11-17 ET
Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock
2020-11-16 21:01 ET
Kodiak Sciences Announces Proposed Offering of Common Stock
2020-11-16 11:53 ET
Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration
2020-11-12 21:12 ET
Kodiak Sciences to Present at Upcoming Conferences
2020-11-12 04:27 ET
Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting
2020-11-09 10:30 ET
Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights
2020-10-29 13:00 ET
AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets
2020-10-05 13:02 ET
Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion
2020-09-02 20:08 ET
Kodiak Sciences to Present at Upcoming Conferences
2020-08-10 09:30 ET
Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights
2020-07-16 20:38 ET
Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress
2020-07-07 12:38 ET
Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar
2020-05-28 12:22 ET
Kodiak Sciences to Present at Upcoming Conferences
2020-05-11 20:13 ET
Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference
2020-05-11 09:30 ET
Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights
2020-05-08 20:30 ET
Kodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020
2020-04-02 20:08 ET
Kodiak Sciences Appoints Charles Bancroft to Board of Directors
2020-03-24 12:51 ET
"Kodiak" and "Kodiak Sciences" Trademarks Registered to Kodiak Sciences Inc. for Its Exclusive Use
2020-03-16 09:30 ET
Kodiak Sciences Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
2020-02-27 11:00 ET
Kodiak Sciences to Present at Upcoming Conferences
2020-02-05 21:01 ET
Kodiak Sciences Announces Upcoming Presentation of Additional KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2020 Meeting
2019-12-19 21:01 ET
Kodiak Sciences Appoints Taiyin Yang, Ph.D., to Board of Directors
2019-12-06 21:15 ET
Kodiak Sciences Announces Closing of $317.4 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2019-12-04 02:07 ET
Kodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stock
2019-12-03 14:31 ET
Thinking about buying stock in E*TRADE, Kodiak Sciences, Micron Technology, Nio, or Wells Fargo?
2019-12-02 22:00 ET
Kodiak Sciences Announces Proposed Offering of Common Stock
2019-12-02 12:00 ET
Kodiak Sciences to Present at the Evercore ISI HealthCONx Conference
2019-12-02 11:00 ET
Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
2019-11-12 10:30 ET
Kodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights
2019-11-08 12:00 ET
Kodiak Sciences to Report Third Quarter 2019 Results and Host Business Highlights Webcast on November 12, 2019
2019-10-11 10:00 ET
Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301
2019-10-10 23:39 ET
Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration
2019-10-07 10:00 ET
Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting
2019-09-15 10:08 ET
Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting
2019-09-04 22:30 ET
Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting
2019-08-14 09:30 ET
Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights
2019-08-08 10:00 ET
Kodiak Sciences to Present at Wedbush PacGrow Healthcare Conference
2019-07-24 11:00 ET
Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting
2019-05-30 23:27 ET
Kodiak Sciences to Present at the Jefferies 2019 Healthcare Conference
2019-05-15 10:00 ET
Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights
2019-04-25 20:05 ET
Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting

SEC forms

Show financial reports only

SEC form 10
2026-05-07 20:15 ET
Kodiak Sciences published news for 2026 q1
SEC form 8
2026-05-07 20:00 ET
Kodiak Sciences published news for 2026 q1
SEC form 8
2026-05-07 20:00 ET
Kodiak Sciences published news for 2026 q1
SEC form 10
2026-03-31 21:02 ET
Kodiak Sciences published news for 2025 q4
SEC form 8
2026-03-31 20:54 ET
Kodiak Sciences published news for 2025 q4
SEC form 8
2026-03-31 20:54 ET
Kodiak Sciences published news for 2025 q4
SEC form 8
2026-03-27 01:56 ET
Kodiak Sciences published news for 2025 q4
SEC form 8
2026-03-27 01:56 ET
Kodiak Sciences published news for 2025 q4
SEC form 8
2025-12-18 21:25 ET
Kodiak Sciences published news for 2025 q3
SEC form 8
2025-12-18 21:25 ET
Kodiak Sciences published news for 2025 q3
SEC form 8
2025-12-18 21:25 ET
Kodiak Sciences published news for 2025 q3
SEC form 10
2025-11-13 16:12 ET
Kodiak Sciences published news for 2025 q3
SEC form 8
2025-11-13 16:05 ET
Kodiak Sciences published news for 2025 q3
SEC form 8
2025-11-13 16:05 ET
Kodiak Sciences published news for 2025 q3
SEC form 10
2025-08-13 20:11 ET
Kodiak Sciences published news for 2025 q2
SEC form 8
2025-08-13 20:00 ET
Kodiak Sciences published news for 2025 q2
SEC form 8
2025-08-13 20:00 ET
Kodiak Sciences published news for 2025 q2
SEC form 10
2025-05-14 20:34 ET
Kodiak Sciences reported for 2025 q1
SEC form 10
2025-05-14 00:00 ET
Kodiak Sciences reported for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Kodiak Sciences published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Kodiak Sciences published news for 2025 q1
SEC form 10
2025-03-27 16:20 ET
Kodiak Sciences reported for 2024 q4
SEC form 8
2025-03-27 16:10 ET
Kodiak Sciences published news for 2024 q4
SEC form 8
2025-03-27 16:10 ET
Kodiak Sciences published news for 2024 q4
SEC form 10
2025-03-27 00:00 ET
Kodiak Sciences reported for 2024 q4
SEC form 10
2024-11-14 16:10 ET
Kodiak Sciences published news for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Kodiak Sciences published news for 2024 q3
SEC form 8
2024-11-14 00:00 ET
Kodiak Sciences published news for 2024 q3
SEC form 8
2024-11-14 00:00 ET
Kodiak Sciences published news for 2024 q3
SEC form 10
2024-08-14 16:10 ET
Kodiak Sciences published news for 2024 q2
SEC form 8
2024-08-14 16:05 ET
Kodiak Sciences published news for 2024 q2
SEC form 8
2024-08-14 16:05 ET
Kodiak Sciences published news for 2024 q2
SEC form 10
2024-08-14 00:00 ET
Kodiak Sciences published news for 2024 q2
SEC form 10
2024-05-15 16:15 ET
Kodiak Sciences reported for 2024 q1
SEC form 8
2024-05-15 16:10 ET
Kodiak Sciences published news for 2024 q1
SEC form 8
2024-05-15 16:10 ET
Kodiak Sciences published news for 2024 q1
SEC form 10
2024-05-15 00:00 ET
Kodiak Sciences reported for 2024 q1
SEC form 10
2024-03-28 16:05 ET
Kodiak Sciences reported for 2023 q4
SEC form 8
2024-03-28 07:15 ET
Kodiak Sciences published news for 2023 q4
SEC form 8
2024-03-28 07:15 ET
Kodiak Sciences published news for 2023 q4
SEC form 10
2024-03-28 00:00 ET
Kodiak Sciences reported for 2023 q4
SEC form 10
2023-11-14 16:30 ET
Kodiak Sciences published news for 2023 q3
SEC form 8
2023-11-14 16:10 ET
Kodiak Sciences published news for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Kodiak Sciences published news for 2023 q3
SEC form 10
2023-08-14 16:33 ET
Kodiak Sciences published news for 2023 q2
SEC form 6
2023-08-14 16:12 ET
Kodiak Sciences reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Kodiak Sciences published news for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Kodiak Sciences reported for 2023 q2
SEC form 6
2023-07-24 06:45 ET
Kodiak Sciences published news for 2023 q2
SEC form 8
2023-07-24 00:00 ET
Kodiak Sciences published news for 2023 q2
SEC form 10
2023-05-15 16:11 ET
Kodiak Sciences reported for 2023 q1
SEC form 6
2023-05-15 16:06 ET
Kodiak Sciences reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Kodiak Sciences reported for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Kodiak Sciences reported for 2023 q1
SEC form 6
2023-04-25 16:01 ET
Kodiak Sciences published news for 2023 q1
SEC form 10
2023-03-28 16:31 ET
Kodiak Sciences reported for 2022 q4
SEC form 6
2023-03-28 16:20 ET
Kodiak Sciences reported for 2022 q4
SEC form 10
2023-03-28 00:00 ET
Kodiak Sciences reported for 2022 q4
SEC form 8
2023-03-28 00:00 ET
Kodiak Sciences reported for 2022 q4
SEC form 10
2022-11-09 16:15 ET
Kodiak Sciences published news for 2022 q3
SEC form 6
2022-11-09 16:08 ET
Kodiak Sciences reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Kodiak Sciences published news for 2022 q3
SEC form 8
2022-11-09 00:00 ET
Kodiak Sciences reported for 2022 q3
SEC form 10
2022-08-09 17:02 ET
Kodiak Sciences published news for 2022 q2
SEC form 6
2022-08-09 16:44 ET
Kodiak Sciences reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Kodiak Sciences published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Kodiak Sciences reported for 2022 q2
SEC form 6
2022-08-08 07:00 ET
Kodiak Sciences published news for 2022 q2
SEC form 6
2022-06-07 18:21 ET
Kodiak Sciences published news for 2022 q1
SEC form 6
2022-05-10 16:16 ET
Kodiak Sciences reported for 2022 q1
SEC form 10
2022-05-10 16:07 ET
Kodiak Sciences reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Kodiak Sciences reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Kodiak Sciences reported for 2022 q1
SEC form 6
2022-04-28 16:07 ET
Kodiak Sciences published news for 2022 q1
SEC form 10
2022-03-01 16:31 ET
Kodiak Sciences published news for 2021 q4
SEC form 6
2022-03-01 16:16 ET
Kodiak Sciences published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
Kodiak Sciences published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Kodiak Sciences published news for 2021 q4
SEC form 6
2022-02-23 06:30 ET
Kodiak Sciences published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
Kodiak Sciences published news for 2021 q4
SEC form 10
2021-11-09 17:10 ET
Kodiak Sciences published news for 2021 q3
SEC form 6
2021-11-09 16:34 ET
Kodiak Sciences published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Kodiak Sciences published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Kodiak Sciences published news for 2021 q3
SEC form 6
2021-10-15 17:20 ET
Kodiak Sciences published news for 2021 q3
SEC form 6
2021-09-13 17:00 ET
Kodiak Sciences published news for 2021 q2
SEC form 6
2021-09-01 06:08 ET
Kodiak Sciences published news for 2021 q2
SEC form 6
2021-09-01 06:02 ET
Kodiak Sciences published news for 2021 q2
SEC form 10
2021-08-09 16:23 ET
Kodiak Sciences published news for 2021 q2
SEC form 6
2021-08-09 16:04 ET
Kodiak Sciences published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Kodiak Sciences published news for 2021 q2
SEC form 8
2021-08-09 00:00 ET
Kodiak Sciences published news for 2021 q2
SEC form 6
2021-07-22 21:01 ET
Kodiak Sciences published news for 2021 q2
SEC form 6
2021-06-07 21:04 ET
Kodiak Sciences published news for 2021 q1
SEC form 10
2021-05-10 17:13 ET
Kodiak Sciences published news for 2021 q1
SEC form 6
2021-05-10 06:03 ET
Kodiak Sciences published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Kodiak Sciences published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Kodiak Sciences published news for 2021 q1
SEC form 6
2021-04-28 16:34 ET
Kodiak Sciences published news for 2021 q1
SEC form 10
2021-03-01 17:23 ET
Kodiak Sciences published news for 2020 q4
SEC form 6
2021-03-01 06:04 ET
Kodiak Sciences published news for 2020 q4
SEC form 6
2020-11-18 16:18 ET
Kodiak Sciences published news for 2020 q3
SEC form 10
2020-11-09 16:33 ET
Kodiak Sciences published news for 2020 q3
SEC form 6
2020-11-09 06:06 ET
Kodiak Sciences published news for 2020 q3